1. MindMed granted options for 31,500 shares to new employees. 2. Options vest over four years, starting 25% after one year. 3. Grants approved by Compensation Committee under NASDAQ rules. 4. MindMed focuses on treatments for brain health disorders. 5. The closing price on grant date will be the exercise price.
FAQ
Why Neutral?
Issuance of options impacts employee incentives but lacks immediate market effects. Historical examples show that such grants often have minimal direct impact on stock prices yet can influence long-term performance if tied to company success.
How important is it?
While the employee stock options are routine, they signify internal confidence in company growth. The potential alignment of employee goals with corporate objectives is essential for long-term stock performance.
Why Long Term?
The grants will incentivize employee retention and performance over several years. Similar companies have seen gradual stock performance improvements related to employee motivation initiatives.
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 31,500 common shares of the Company (the "Options") with an effective grant date of December 15, 2025. The Options have an exercise price equal to the closing price of MindMed's common shares on the date of the grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment.
The Options were granted as a material inducement to each employee's employment and were approved by MindMed's Compensation Committee on December 14, 2025, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The Options were granted outside MindMed's equity incentive plans.
About MindMed
MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251215867745/en/
For further information, please contact:
Investors:
Gitanjali Jain
VP, Head of Investor Relations
ir@mindmed.co
Media:
media@mindmed.co